These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34587230)

  • 21. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
    Gagelmann N; Ayuk F; Atanackovic D; Kröger N
    Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
    Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
    Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
    Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
    N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
    Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
    Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
    Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma.
    Li Z; Que Y; Wang D; Lu J; Li C; Xu M; Wang Z; Yu Q; Long X; An N; Xiao Y; Li C
    Thromb Res; 2023 Jul; 227():62-70. PubMed ID: 37235950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
    Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
    Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
    Chen D; Wang X; Chen Z; Jiang S; Jiang H; Fu W; Xiang F; Sun X; Du J
    Am J Hematol; 2022 Dec; 97(12):E478-E481. PubMed ID: 36197023
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
    Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
    Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
    Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
    J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease.
    Li W; Liu M; Yuan T; Yan L; Cui R; Deng Q
    Hematol Oncol; 2022 Apr; 40(2):223-232. PubMed ID: 34942032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
    Zu C; Wang K; Zhang Q; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):160-166. PubMed ID: 36161295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma.
    Ma T; Shi J; Xiao Y; Bian T; Wang J; Hui L; Wang M; Liu H
    Front Immunol; 2021; 12():724411. PubMed ID: 34867949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
    D'Agostino M; Raje N
    Leukemia; 2020 Jan; 34(1):21-34. PubMed ID: 31780814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
    Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement.
    Wang Y; Zu C; Teng X; Yang L; Zhang M; Hong R; Zhao H; Cui J; Xu H; Hongsheng AC; Hu Y; Huang H
    J Immunother; 2022 Jan; 45(1):25-34. PubMed ID: 34874329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Banerjee R; Marsal J; Huang CY; Lo M; Thiruvengadam SK; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
    Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.